What types of blood system diseases is Venetoclax (Venetoclax) suitable for?

Venetoclax, also known as Venetoclax, is a targeted drug used to treat certain types of blood disorders. By inhibiting the activity of BCL-2 protein, it enhances the sensitivity of cancer cells to chemotherapy drugs and promotes apoptosis of cancer cells. Venetoclax is widely used in the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

Venetoclax is mainly used for chronic lymphocytic leukemia (CLL). CLL is a type of leukemia derived from B lymphocytes. It usually presents with abnormal immune system function and makes patients susceptible to infection. The expression of BCL-2 protein is abnormally increased in CLL cells, which helps tumor cells escape the normal apoptosis process and causes tumor cells to grow too fast. Venetoclax can effectively control the disease by inhibiting the function of BCL-2 protein and promoting the death of CLL cells. It is approved to treat patients with previously treated CLL whose disease has relapsed or is resistant.

Venetoclax is also used to treat acute myeloid leukemia (AML), especially in cases of certain genetic mutations or chromosomal abnormalities. AML is a malignant tumor derived from bone marrow. It usually progresses rapidly and is difficult to treat. In some AML patients, the expression of BCL-2 protein is significantly increased, making tumor cells less likely to enter the apoptosis program. Venetoclax effectively inhibits BCL-2, thereby enhancing the effectiveness of chemotherapy drugs, especially when used in combination with chemotherapy drugs. Studies have shown that venetoclax has achieved good therapeutic effects in some AML patients, especially those with specific gene mutations.

The use of venetoclax is not limited to CLL and AML, but can also be used in combination with other treatments to improve efficacy. In some cases, venetoclax can be combined with other targeted therapies or chemotherapy drugs to enhance the effectiveness of treatment, especially in patients with CLL or AML.When patients develop resistance to a single treatment. Venetoclax offers a new treatment option for patients who cannot tolerate chemotherapy or who are unable to continue treatment due to side effects.

Reference materials:https://www.venclexta.com/